Form 4: QuidelOrtho CEO Brian Blaser Awarded 52,390 Restricted Stock Units
SEC Form 4 Filing
QuidelOrtho's President and CEO, Brian J. Blaser, was granted 52,390 restricted stock units, which will vest over the next three years.
Summary
- Brian J. Blaser, President and CEO of QuidelOrtho Corp, was granted 52,390 restricted stock units on January 29, 2025.
- These restricted stock units represent the right to receive one share of QuidelOrtho common stock per unit.
- The vesting schedule for these units is staggered, with 34,926 shares vesting in equal installments on January 29, 2026 and January 29, 2027.
- The remaining 17,464 shares will vest on January 29, 2028.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. The sentiment is neutral to slightly positive.
Positives
- The grant of restricted stock units aligns the CEO's interests with those of the shareholders.
- The vesting schedule encourages long-term performance and retention of the CEO.
Risks
- The value of the restricted stock units is dependent on the future performance of QuidelOrtho's stock price.
Future Outlook
The vesting of the restricted stock units is tied to future dates, incentivizing the CEO to focus on long-term value creation for the company.
Industry Context
The granting of restricted stock units is a common practice in corporate America to incentivize and retain key executives.
Comparison to Industry Standards
- Many companies in the healthcare and diagnostics industry use restricted stock units as part of their executive compensation packages.
- The vesting schedule of these units is fairly standard, with vesting occurring over a period of several years to encourage long-term performance.
- Companies like Abbott Laboratories and Danaher Corporation also use similar equity-based compensation strategies for their executives.
Stakeholder Impact
- Shareholders may view this as a positive sign of management's commitment to the company's long-term success.
- Employees may see this as a sign of stability and confidence in the company's leadership.
Key Dates
| Date | Description |
|---|---|
| 01/29/2025 | Date of the grant of 52,390 restricted stock units. |
| 01/29/2026 | First vesting date for 17,463 shares of the restricted stock units. |
| 01/29/2027 | Second vesting date for 17,463 shares of the restricted stock units. |
| 01/29/2028 | Final vesting date for 17,464 shares of the restricted stock units. |
| 01/31/2025 | Date of the filing of the SEC Form 4. |
Keywords
restricted stock units, stock options, executive compensation, QuidelOrtho, Brian Blaser, equity awards, vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.